Efficacy and safety of abemaciclib alone and with PI3K / mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial
Cancer Medicine · 2023
DOI: 10.1002/cam4.6621 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von E Gabriela Chiorean und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington School of Medicine, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Pancreatic Neoplasms, Quinolones. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Pancreatic ductal adenocarcinomas (PDAC) are characterized by frequent cell cycle pathways aberrations. This study evaluated safety and efficacy of abemaciclib, a cyclin‐dependent kinase 4 and 6 inhibitor, as monotherapy or in combination with PI3K/mTOR dual inhibitor LY3023414 or TGFβ inhibitor galunisertib versus standard of care (SOC) chemotherapy in patients with pretreated metastatic PDAC.
Methods
This Phase 2 open‐label study enrolled patients with metastatic PDAC who progressed after 1–2 prior therapies. Patients were enrolled in a safety lead‐in (abemaciclib plus galunisertib) followed by a 2‐stage randomized design. Stage 1 randomization was planned 1:1:1:1 for abemaciclib, abemaciclib plus LY3023414, abemaciclib plus galunisertib, or SOC gemcitabine or capecitabine. Advancing to Stage 2 required a disease control rate (DCR) difference ≥0 in abemaciclib‐containing arms versus SOC. Primary objectives for Stages 1 and 2 were DCR and progression‐free survival (PFS), respectively. Secondary objectives included response rate, overall survival, safety, and pharmacokinetics.
Results
One hundred and six patients were enrolled. Abemaciclib plus galunisertib did not advance to Stage 1 for reasons unrelated to safety or efficacy. Stage 1 DCR was 15.2% with abemaciclib monotherapy, 12.1% with abemaciclib plus LY3023414, and 36.4% with SOC. Median PFS was 1.7 months (95% CI: 1.4–1.8), 1.8 months (95% CI: 1.3–1.9), and 3.3 months (95% CI: 1.1–5.7), respectively. No arms advanced to Stage 2. No new safety signals were identified.
Conclusion
In patients with pretreated metastatic PDAC, abemaciclib‐based therapy did not improve DCRs or PFS compared with SOC chemotherapy. No treatment arms advanced to Stage 2. Abemaciclib remains investigational in patients with PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Washington School of Medicine, Seattle, Washington, USA.
- Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Virginia Mason Hospital and Medical Center, Seattle, Washington, USA.
- Division of Clinical Skills Training, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- Therapeutic and Research Center of Pancreatic Cancer, Taipei Veterans General Hospital, Taipei, Taiwan.
ORCID-Profile: E Gabriela Chiorean, Joan Maurel
Förderung
- Eli Lilly and Company
Zitieren
APA
Chiorean, E. G., Picozzi, V., Li, C. P., Peeters, M., Maurel, J., Singh, J., Golan, T., Blanc, J. F., Chapman, S. C., Hussain, A. M., Johnston, E. L., & Hochster, H. S. (2023). Efficacy and safety of abemaciclib alone and with PI3K / mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial. Cancer Medicine. https://doi.org/10.1002/cam4.6621
Vancouver
Chiorean EG, Picozzi V, Li CP, Peeters M, Maurel J, Singh J, et al. Efficacy and safety of abemaciclib alone and with PI3K / mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial. Cancer Medicine. 2023. doi:10.1002/cam4.6621
BibTeX
@article{Chiorean2023,
author = {Chiorean, E Gabriela and Picozzi, Vincent and Li, Chung-Pin and Peeters, Marc and Maurel, Joan and Singh, Jaswinder and Golan, Talia and Blanc, Jean-Frédéric and Chapman, Sonya C and Hussain, Anwar M and Johnston, Erica L and Hochster, Howard S},
title = {Efficacy and safety of abemaciclib alone and with PI3K / mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6621}
}
EUVIMED